Search results
Added:
1 year ago
As part of e-SPACE Cardio-Renal-Metabolic 2024, Prof Gianluigi Savarese, Dr Alice Cheng, Dr Adeera Levin, Prof Antonio Ceriello, Dr Shelley Zieroth and Prof Giuseppe Rosano discuss managing patients with CRM.
View more
Added:
1 year ago
As part of e-SPACE Cardio-Renal-Metabolic 2024, Prof John Cleland, Prof Gerasimos Filippatos, Prof Ewa Jankowska, Prof David Wheeler, Dr Kieran Docherty discuss anaemia and iron deficiency.
View more
Added:
1 year ago
As part of e-SPACE Cardio-Renal-Metabolic 2024, Prof Ahmed Bennis, Dr Ileana L Pina, Dr Giulia Ferrannini, Dr Chiadi Ndumele, Prof Rodica Pop-Busui and Prof Mitja Lainscak discuss the epidemiology and pathophysiology of CRM disease.
View more
Added:
1 year ago
As part of e-SPACE Cardio-Renal-Metabolic 2024, Prof Intissar Haddiya, Dr Lars Lund, Prof Marco Metra, Prof Nikolaus Marx, Prof Peter Rossing and Prof Giuseppe Rosano discuss guideline directed therapy for CRM disease.
View more
Added:
5 months ago
AHA Scientific Sessions 2025 - Dr Nils Krüger (Brigham and Women's Hospital, US) joins us to discuss findings from the TIRZSEMA-CVOT (NCT07096063) study, examining real-world cardiovascular outcomes with tirzepatide and semaglutide in patients with type 2 diabetes at cardiovascular risk.This retrospective cohort study utilized three national US claims databases to evaluate over 887,000 patients…
View more
Added:
10 months ago
ERA 2025 - Dr Ellen Linnea Freese Ballegaard (Copenhagen University Hospital, Copenhagen, DK) joins us to discuss a study investigating guideline-based management of CKD and evaluate the associated risk of cardio-renal outcomes. 315,636 patients were identified from nationwide Danish health care registers between 2011 and 2022 and enrolled in the study. The primary outcome measure was a composite…
View more
Added:
1 year ago
ACC 25 - SOUL shows oral semaglutide was superior to placebo in reducing the incidence of 3-point MACE in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease.Late-breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Darren McGuire (UT Southwestern Medical Center, Dallas, US) to discuss the findings from the…
View more
Added:
1 year ago
Outcomes from a new CV disease risk assessment tool show significant improvements in CV, kidney and metabolic health after bariatric surgery. The study also found a reduction in estimated 10 year risk of developing total CV disease and a reduction in the risk of developing heart failure one year after bariatric surgery.In this short interview, Dr Danxia Yu (Vanderbilt University Medical Center,…
View more
Added:
2 weeks ago
American College of Cardiology Congress 2026 – Dr Pam Taub (University of California San Diego, La Jolla, US) joins us to discuss results from the RECOVER-Autonomic platform trial (NCT06305806; Kanecia Obie Zimmerman), evaluating the impact of ivabradine on orthostatic intolerance, quality of life, and heart rate in post-COVID POTS.This randomised, placebo-controlled appendix trial enrolled 181…
View more
Added:
1 year ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median…
View more